These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 34335964)

  • 1. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
    Wu MJ; Chen CJ; Lin TY; Liu YY; Tseng LL; Cheng ML; Chuu CP; Tsai HK; Kuo WL; Kung HJ; Wang WC
    Theranostics; 2021; 11(16):7779-7796. PubMed ID: 34335964
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer.
    Tang DE; Dai Y; He JX; Lin LW; Leng QX; Geng XY; Fu DX; Jiang HW; Xu SH
    J Pathol; 2020 Oct; 252(2):101-113. PubMed ID: 32617978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer.
    Duan L; Chen YA; Liang Y; Chen Z; Lu J; Fang Y; Cao J; Lu J; Zhao H; Pong RC; Hernandez E; Kapur P; Tran TAT; Smith T; Martinez ED; Ahn JM; Hsieh JT; Luo JH; Liu ZP
    Biomed Pharmacother; 2023 Feb; 158():114077. PubMed ID: 36495660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
    Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
    Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulated KDM4B promotes prostate cancer cell proliferation by activating autophagy.
    Sha J; Han Q; Chi C; Zhu Y; Pan J; Dong B; Huang Y; Xia W; Xue W
    J Cell Physiol; 2020 Mar; 235(3):2129-2138. PubMed ID: 31468537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.
    Liu JS; Fang WK; Yang SM; Wu MC; Chen TJ; Chen CM; Lin TY; Liu KL; Wu CM; Chen YC; Chuu CP; Wang LY; Hsieh HP; Kung HJ; Wang WC
    J Biomed Sci; 2022 May; 29(1):29. PubMed ID: 35534851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation.
    Duan L; Chen Z; Lu J; Liang Y; Wang M; Roggero CM; Zhang QJ; Gao J; Fang Y; Cao J; Lu J; Zhao H; Dang A; Pong RC; Hernandez E; Chang CM; Hoang DT; Ahn JM; Xiao G; Wang RT; Yu KJ; Kapur P; Rizo J; Hsieh JT; Luo J; Liu ZP
    Nucleic Acids Res; 2019 Dec; 47(22):11623-11636. PubMed ID: 31647098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity.
    Pornour M; Jeon HY; Ryu H; Khadka S; Xu R; Chen H; Hussain A; Lam HM; Zhuang Z; Oo HZ; Gleave M; Dong X; Wang Q; Barbieri C; Qi J
    Proc Natl Acad Sci U S A; 2024 Jul; 121(31):e2403331121. PubMed ID: 39052835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
    Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
    Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.
    Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q
    Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JMJD2A promotes the development of castration-resistant prostate cancer by activating androgen receptor enhancer and inhibiting the cGAS-STING pathway.
    Cai X; Yu X; Tang T; Xu Y; Wu T
    Mol Carcinog; 2024 Sep; 63(9):1682-1696. PubMed ID: 38818897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1.
    Qiu MT; Fan Q; Zhu Z; Kwan SY; Chen L; Chen JH; Ying ZL; Zhou Y; Gu W; Wang LH; Cheng WW; Zeng J; Wan XP; Mok SC; Wong KK; Bao W
    Oncotarget; 2015 Oct; 6(31):31702-20. PubMed ID: 26397136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
    Singh KB; Ji X; Singh SV
    Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover.
    Coffey K; Rogerson L; Ryan-Munden C; Alkharaif D; Stockley J; Heer R; Sahadevan K; O'Neill D; Jones D; Darby S; Staller P; Mantilla A; Gaughan L; Robson CN
    Nucleic Acids Res; 2013 Apr; 41(8):4433-46. PubMed ID: 23435229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
    Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
    Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of histone demethylase KDM4B in Myc signaling in neuroblastoma.
    Yang J; AlTahan AM; Hu D; Wang Y; Cheng PH; Morton CL; Qu C; Nathwani AC; Shohet JM; Fotsis T; Koster J; Versteeg R; Okada H; Harris AL; Davidoff AM
    J Natl Cancer Inst; 2015 Jun; 107(6):djv080. PubMed ID: 25925418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.